AnTix Holdings, Inc.: debt financing — Innovative MedTech sells $97,750 convertible note to Labrys Fund, netting $77K

AnTix Holdings, Inc.

Sold $97,750 convertible promissory note to Labrys Fund II, L.P. for $85,000; net funding $77,000 after legal and placement agent fees.
Note matures in 12 months, accrues 12% fixed interest, convertible at 71% of lowest closing bid price over prior 10 trading days.
Conversion capped at 4.99% beneficial ownership (9.99% after 61 days with notice); holder deducts $1,500 per conversion for fees.
Proceeds earmarked for business development and general working capital; not for insider debt repayment or loans.
Issued under Section 4(a)(2) exemption from registration; includes customary representations, warranties, and closing conditions.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

AnTix Holdings, Inc. incurred convertible notes of $97,750 with Labrys Fund II, L.P. at a one-time interest charge of 12% on the principal amount at issuance maturing twelve months following the issue date.

Instrument: convertible notes
Principal: $97,750
Counterparty: Labrys Fund II, L.P.
Rate: a one-time interest charge of 12% on the principal amount at issuance
Maturity: twelve months following the issue date
Event: incurrence

Exact text from the filing

Effective as of August 6, 2025, Innovative MedTech, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ SPA ”) with Labrys Fund II, L.P., a Delaware limited partnership (“ Labrys ”), pursuant to which the Company sold, and Labrys purchased, a convertible promissory note in the principal amount of $97,750 (the “ Note ”) for a purchase price of $85,000 (the “ Transaction ”).

View on SEC.gov

317 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001477932-25-005597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.